The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer
Pancreatology · 2024-09 · 24 (6) · 887-893
DOI: 10.1016/j.pan.2024.06.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2024-09. Verfasst von Jonah M Levine und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The NYU Grossman School of Medicine and NYU Langone Health, New York, NY, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Lung Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH.
Abstract (Originalsprache)
BACKGROUND OBJECTIVES: The aim of this study was to determine the role of site-specific metastatic patterns over time and assess factors associated with extended survival in metastatic PDAC. Half of all patients with pancreatic ductal adenocarcinoma (PDAC) present with metastatic disease. The site of metastasis plays a crucial role in clinical decision making due to its prognostic value. METHODS: We examined 56,757 stage-IV PDAC patients from the National Cancer Database (2016-2019), categorizing them by metastatic site: multiple, liver, lung, brain, bone, carcinomatosis, or other. The site-specific prognostic value was assessed using log-rank tests while time-varying effects were assessed by Aalen's linear hazards model. Factors associated with extended survival (>3years) were assessed with logistic regression. RESULTS: Median overall survival (mOS) in patients with distant lymph node-only metastases (9.0 months) and lung-only metastases (8.1 months) was significantly longer than in patients with liver-only metastases (4.6 months, p < 0.001). However, after six months, the metastatic site lost prognostic value. Logistic regression identified extended survivors (3.6 %) as more likely to be younger, Hispanic, privately insured, Charlson-index
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, The NYU Grossman School of Medicine and NYU Langone Health, New York, NY, USA.
- Department of Surgery, The NYU Grossman School of Medicine and NYU Langone Health, New York, NY, USA; Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
- Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Surgery, The NYU Grossman School of Medicine and NYU Langone Health, New York, NY, USA. Electronic address: Ammar.Javed@NYULangone.org.
Förderung
- NCI NIH HHS
- NIH
Zitieren
APA
Levine, J. M., Rompen, I. F., Franco, J. C., Swett, B., Kryschi, M. C., Habib, J. R., Diskin, B., Hewitt, D. B., Sacks, G. D., Kaplan, B., Berman, R. S., Cohen, S. M., Wolfgang, C. L., & Javed, A. A. (2024). The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer. Pancreatology, 24(6), 887-893. https://doi.org/10.1016/j.pan.2024.06.004
Vancouver
Levine JM, Rompen IF, Franco JC, Swett B, Kryschi MC, Habib JR, et al. The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer. Pancreatology. 2024;24(6):887-893. doi:10.1016/j.pan.2024.06.004
BibTeX
@article{Levine2024,
author = {Levine, Jonah M and Rompen, Ingmar F and Franco, Jorge Campos and Swett, Ben and Kryschi, Maximilian C and Habib, Joseph R and Diskin, Brian and Hewitt, D Brock and Sacks, Greg D and Kaplan, Brian and Berman, Russel S and Cohen, Steven M and Wolfgang, Christopher L and Javed, Ammar A},
title = {The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer},
journal = {Pancreatology},
year = {2024},
volume = {24},
number = {6},
pages = {887--893},
doi = {10.1016/j.pan.2024.06.004}
}
EUVIMED